GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
A shelf registration statement relating to this offering was filed with
the Securities and Exchange Commission (SEC) on March 17, 2015 and
declared effective by the SEC on March 24, 2015. The offering was made
only by means of a written prospectus and prospectus supplement that
form a part of the registration statement. The final prospectus
supplement and accompanying prospectus were filed with the SEC on
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530006192/en/
News Provided by Acquire Media